# Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

> **NCT05766813** · PHASE2 · RECRUITING · sponsor: **Intra-Cellular Therapies, Inc.** · enrollment: 132 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Lenrispodun
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05766813
- **Lead sponsor:** Intra-Cellular Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-13
- **Primary completion:** 2025-09
- **Final completion:** 2025-10
- **Target enrollment:** 132 (ESTIMATED)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05766813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05766813, "Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05766813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*